The Pharma Letter Podcast — Episode 2 — Non-opioid analgesics

Simon Wentworth

22 July 2021

podcast-episode2

More on this story...

Virtual launch for non-opioid analgesic Anjeso

23 April 2020

US FDA approves non-opioid analgesic from Baudax Bio

21 February 2020

Analgesics market to hit expected to hit $79 billion by 2028

16 August 2018

The Pharma Letter Podcast — Episode 4 — The state of biotech investing

1 September 2021

Companies featured in this story

More ones to watch >

Today's issue

Alloy and Takeda team up on CAR-T cell platform

Alloy and Takeda team up on CAR-T cell platform

21 November 2024

Eisai announces launch of Rozebalamin and Tasfygo

21 November 2024

Merck: a relentless pursuit of the best outcomes for the entire MS community

21 November 2024

Cidara to raise up to $105 million in private placement

21 November 2024

Novartis upgrades mid-term guidance; buys Kate Thera

21 November 2024

FDA approves Jazz’s Ziihera for HER2+ biliary tract cancer

21 November 2024

Lilly and Laekna team up on novel obesity drugs

21 November 2024

Company Spotlight

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.

More Features in Biotechnology

Alloy and Takeda team up on CAR-T cell platform

21 November 2024

Cidara to raise up to $105 million in private placement

21 November 2024

FDA approves Jazz’s Ziihera for HER2+ biliary tract cancer

21 November 2024

Lilly and Laekna team up on novel obesity drugs

21 November 2024

Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze